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Adam Gladwish1, Geordi Pang1,2, Patrick Cheung1,2, Laura D’Alimonte2, Andrea Deabreu2 and Andrew Loblaw1,2,3*Abstract
Background: To determine prostate displacement during extreme hypofractionated volume modulated arc
radiotherapy (VMAT) using pre- and post-treatment orthogonal images with three implanted gold seed fiducial
markers.
Methods: A total of 150 image pairs were obtained from 30 patients who underwent extreme hypofractionated
radiotherapy to a dose of 40 Gy in five fractions on standard linear accelerators. Position verification was obtained
with orthogonal x-rays before and after treatment and were used to determine intra-fraction prostate displacement.
Results: The mean prostate displacements were 0.03 ± 1.23 mm (1SD), 0.18 ± 1.55 mm, and 0.37 ± 1.95 mm in the
left-right, superior-inferior, and anterior-posterior directions, respectively. The mean 3D displacement was 2.32 ±
1.55 mm. Only 6 (4%) fractions had a 3D displacement of >5 mm. The average time of treatment delivery for a
given fraction was 195 ± 59 seconds.
Conclusions: The mean intra-fraction prostate displacement during a course of extreme hypofractionated radiotherapy
delivered via VMAT, continues to be small. Clinical margins typically used in a similar fixed-angle IMRT treatment are
adequate. The use of VMAT in further extreme hypofractionation may limit prostatic motion uncertainties that would
be otherwise be associated with longer treatment times.
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Prostate cancer is the most commonly diagnosed cancer
amongst Canadian men, with approximately 26,000 new
diagnoses in 2011 [1]. Radiotherapy remains a mainstain
of treatment in a large proportion of these patients. Ran-
domized trials have shown that higher doses of radio-
therapy (RT) result in improved biochemical disease free
survival, but at the potential cost of increased rectal and
urinary toxicity when using traditional 3-dimensional
conformal RT (3DCRT) techniques [2,3]. More advanced
RT techniques such as intensity-modulated radiotherapy
(IMRT) have been shown to be able to deliver these in-
creased doses with less toxicity as compared to 3DCRT [3].* Correspondence: andrew.loblaw@sunnybrook.ca
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unless otherwise stated.As with any radiotherapy treatment, motion, both
intra and inter-fraction is a source of uncertainty. Be-
cause of this uncertainty, a margin is added to the clin-
ical target volume (CTV) in creating the planning target
volume (PTV). According to ICRU 83, the margin used
to create the PTV should account for both internal tar-
get motion and day-to-day setup variations [4]. In gen-
eral, smaller margins may reduce normal tissue toxicity
but at the cost of an increased risk of geographical miss
[5], while larger margins may maximize tumor control
but at the cost of higher normal tissue complications.
Accurate characterization of prostate motion may help to
determine the optimal margin to maximize complication-
free disease-free survival.
Most studies of intra-fraction prostate motion have
used conventional 1.8-2 Gy fractions [6,7]. With the dis-
covery of a low alpha-beta ratio for prostate cancer resul-
ting in an increased sensitivity to high dose per fractional Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tionated RT [10,11]. Accurate margins are arguably more
pertinent in the hypofractionated setting, as longer treat-
ment times lead to a greater potential for intra-fraction
motion and higher doses per fraction mean that geograph-
ical misses represent a greater percentage of total dose
delivered [6]. This is obviously further accentuated as the
degree of hypofractionation increases.
We have previously reported on our experience with
prostate motion during extreme hypofractionation (<7
total fractions) based on pre and post-therapy imaging
of implanted prostatic fiducial markers [12]. This work
was based on conventional fixed-angle RT, which utilizes
a planned number of beam angles and achieves intensity
modulation via a ‘step-and-shoot’ manipulation of the
multi-leaf collimator (MLC). Volume modulated arc ther-
apy (VMAT), which delivers radiation continuously during
a 360 degree arc of the linear accelerator while modulating
intensity via both fluence output and MLC manipulation,
has been shown to reduce treatment times without
compromising dose distributions as compared to standard
fixed-angle RT in prostate cancer [13]. Our institution, is
currently involved in two clinical trials investigating pros-
tate hypofractionated accelerated radiotherapy (pHART),
and is utilizing VMAT for treatment delivery. As part of the
quality assurance for these studies, portal images of im-
planted gold seed fiducials were obtained before and after
each fraction. This report examines the translational differ-
ences in prostate location between these images and com-
pares the results to prior work including both standard and
hypofractionated delivery.
Methods and materials
Patients from this work were drawn from two clinical
trials, Prostate Accurately Targeted Radiotherapy Investi-
gation of Overall Treatment Time (PATRIOT) and a
phase II study of dose-escalated, Hypofractionated Radio-
therapy and Androgen Deprivation Therapy for high-risk
prostate cancer (pHART8). Both of these studies were
approved by the Sunnybrook Health Sciences Centre
Research Ethics Board (REB): REB project identification
numbers 385-2011 and 269-2010, respectively. The PAT-
RIOT study randomizes low-intermediate risk prostate
cancer patients to 40Gy in 5 fractions delivered either over
29 days (1 fraction per week) or over 11 days (one fraction
every other day). The pHART8 study delivers 40Gy in 5
fractions over 29 days (as in arm 1 of PATRIOT) to high-
risk prostate cancer patients. Thirty patients were sequen-
tially drawn from the accrual of both trials for analysis in
this study. Treatment planning varied slightly between the
two trials, as described below, but there were no differ-
ences in image acquisition or treatment delivery. Analysis
of intra-fraction motion based on fiducial markers was
identical in both cases, as was margin estimation.Treatment planning
Patients underwent trans-rectal ultrasound-guided inser-
tion of three gold seed fiducials (1 × 3 mm) into the
base, mid-gland, and apex of the prostate. Planning com-
puted tomography was performed one week later. Pa-
tients were simulated and treated with a comfortably full
bladder and empty rectum. No specific medications or
diet were given to empty the rectum prior to simulation
or treatment. A custom vacuum lock bag was used for
immobilization (Vac-Lock, MED-TEC Inc., Orange City,
Iowa, USA).
In patients drawn from the PATRIOT trial, the CTV
included the prostate only. An isotropic 5-mm margin
was added to the CTV to create the PTV. A dose of
40 Gy in five fractions was delivered either once per
week over 29 days or every other day over 11 days (as
described above). An inverse-planning IMRT technique
was used in either case. The Pinnacle v. 9.0 (Philips Ra-
diation Oncology Systems, Fitchburg, WI, USA) software
was used for treatment planning.
In patients drawn from the pHART8 trial, there
were two clinical target volumes. CTV2 included the
prostate only, CTV1 included the inferior 1.5-cm of
seminal vesicles or the entire seminal vesicles for pa-
tients with cT3b disease. A 5-mm margin was added
to each of the CTVs to create PTV1 and PTV2 re-
spectively. An optimized radiotherapy plan was then
developed to treat the PTV2 to 40 Gy in 5 fractions;
PTV1 received 30 Gy in 5 fractions. One radiotherapy
fraction was delivered per week over 29 days. The
Pinnacle v. 9.0 (Philips Radiation Oncology Systems,
Fitchburg, WI, USA) software was again used for
treatment planning.
Treatment delivery
Patients were treated on linear accelerators (Eleka
Synergy, Stockholm, Sweden) equipped with multileaf
collimators using VMAT delivery. For each treatment
delivery, patients were initially set up according to skin
tattoos and in-room lasers. Orthogonal megavoltage
electronic portal images of the prostate were then ob-
tained and the implanted fiducial markers were identi-
fied and confirmed by two medical radiation therapists.
The images were then compared to reference digitally
reconstructed radiographs (DRR) from the treatment
planning system and translational mismatches were
identified using the template matching technique in
iViewGT (Eleka, Stockholm, Sweden). The in-house preci-
sion of the online targeting and correction process was
determined to be 2-mm based on an in-house phantom
study, thus only pre-treatment displacements >2 mm were
corrected prior to starting treatment [12]. Immediately
after treatment, an additional set of orthogonal images
was obtained.
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The minimum prostate motion was calculated as the
difference between the pre- and post-treatment images for
patients who did not require a couch translation prior to
treatment (ie. pre-treatment displacement <2 mm from
reference DRR) or the value of the post-treatment shifts
alone for patients who underwent correction of displace-
ments prior to treatment. The 3-dimensional (3D) dis-
placement was calculated as the vector using the left-right
(LR), superior-inferior (SI), and anterior-posterior (AP)
displacements with the formula D = (LR2 + SI2 + AP2)1/2.
Estimation of margin to account for intra-fraction
prostate motion
Based on the van Herk formula [14], the CTV-PTV mar-
gin needed to cover the CTV with 95% of the dose for




Where ∑ is the standard deviation of the systematic




A total of 27 patients were taken from the PATRIOT trial
and 3 patients were taken from pHART8. A total of 150
sets of pre and post-treatment images were obtained from
the 30 patients (five fractions per patient). Of the 150 frac-
tions delivered, 62 (41.3%) exceeded the 2-mm threshold
on pre-treatment imaging and required corrective shifting
prior to treatment delivery. In general, the displacement of
the prostate was small with only 3 (2%) and zero of the
total fractions with translations >5 mm and >10 mm in at
least one cardinal direction, respectively. The maximum
shift seen in any one direction was 8.5 mm, occurring dur-
ing one fraction in the AP direction. There were two other
displacements >5 mm in the AP direction, and none in
the LR and SI directions. Each of these occurred in
different patients. Displacements were smallest in the LR
directions and largest in the AP direction. The mean
displacements were 0.02 ± 1.23 mm (1SD) to the right,
0.18 ± 2.30 mm caudally, and -0.37 ± 3.50 mm posterior in
the LR, SI, and AP directions, respectively. Figure 1 shows
a histogram of the displacements in each of the three
cardinal directions.
When analyzing the 3D displacement, 6 (4%) fractions
were >5 mm. The maximum 3D displacement was
8.92 mm. The mean 3D displacement was 2.32 ±
1.55 mm. Only a single patient had more than one
fraction with >5 mm displacement, and in that patient it
was two fractions. A histogram of the 3D displacements
is shown in Figure 2.Time of delivery
The average time of treatment delivery for a given frac-
tion was 195 ± 59 seconds. The shortest fraction was de-
livered in 60 seconds. The longest fraction was delivered
in 330 seconds.
CTV-PTV margin
Using the van Herk formula, a margin between the CTV
and planning target volume (PTV) was calculated to ac-
count for intra-fraction motion. The systematic and ran-
dom errors in each cardinal direction, as well as the van
Herk margin are shown in Table 1. Margins of 2.55 mm,
3.16 mm, and 3.86 mm were calculated in the LR, SI,
and AP directions, respectively.
Discussion
Accelerated hypofractionated radiotherapy has been
shown to have potential therapeutic benefits in the treat-
ment of prostate cancer. Previous work by Kron et. al.
has shown that intra-fraction prostatic motion was re-
lated to treatment time [7]. Quon et. al. has shown that
despite this, overall prostate displacement remains small
and typical organ motion margins utilized typical fixed-
angle IMRT margins were adequate for extreme hypofrac-
tionation [12]. Tables 1 and 2 show a comparison of
VMAT and IMRT for hypofractioned delivery as well as a
standard 2Gy fractionation, in terms of treatment motion
and corresponding clinical margin (based on the Van Herk
formula). Included in these comparisons are the afore-
mentioned study by Quon, utilizing fixed-angle IMRT at
7Gy per fraction (total dose of 35Gy) and a previous in-
house study (pHART6) utilizing fixed angle IMRT at 8Gy
per fraction (total dose of 40Gy) [15]. Our results are in
keeping with previous findings that overall prostatic dis-
placement remains small and that standard clinical margin
remain adequate for VMAT hypofractionation.
The largest experience in dealing with intra-fraction
motion in radiotherapy revolves around respiratory
changes. Breathing motion is a cyclical pattern and tech-
niques developed to reduce margins in these cases typic-
ally involve gating or breath-holding. These are so-called
‘snap-shot’ techniques, treating only with the target is at
a certain position, aimed at taking advantage of this
reproducible pattern. Intra-fraction prostatic motion is
thought to be primarily driven by bladder filling and
gaseous rectal emptying/filling, with minor contributions
by respiratory motion and other non-specific internal
processes [16]. This would present largely as AP and SI
displacement, as anatomically the bladder and rectum lie
superior/anterior and posterior respectively. Indeed, in
this study, AP motion was most prominent, followed by
SI motion. This is important, as this pattern is not easily
predicable nor reproducible, but rather driven by a con-
tinuous process (bladder filling) and a random process
Figure 1 Frequency and standard deviation of displacements in the Left-right (LR), Superior-Inferior (SI) and Anterior-Posterior (AP) directions.
Gladwish et al. Radiation Oncology 2014, 9:262 Page 4 of 6
http://www.ro-journal.com/content/9/1/262(gaseous filling/emptying). Various techniques have been
studied to reduce the impact of this motion, including
rectal balloons, anti-gas pre-medications and relaxation
techniques [17-20]. In theory, shortening treatment
times should also be beneficial, as the less time that
transpires between setup and treatment completion, the
less time there would be for these motion events to
occur. Our results indicate that the greatest difference
seen between hypofractionated VMAT and fixed angle
IMRT is in the AP directions, suggesting that uncertain-
ties associated with random gaseous filling/emptying is
reduced with the reduced treatment time.
In this study the average delivery time was just over
3 minutes, roughly half the time of a standard 2Gy
fixed-angle IMRT treatment plan and one-third that ofFigure 2 Frequency of overall displacement in 3-dimensions.an extreme hypofractionated plan [21]. According to
Kron, the expected additional displacement of the pros-
tate with relation to treatment time is 0.2 mm/min, or
approximately 5-10% additional displacement. We note
that in this study, only 6% of fractions had a 3D dis-
placement of >5 mm, as compared to 14% seen in previ-
ous work with hypofractionated fixed-angle IMRT. The
absolute magnitude of this difference is small, and it did
not translate into significant changes in clinical margins
by the Van Herk formula, but one can appreciate that as
set-up uncertainties decline with improved daily imaging,
intra-fraction motion will become increasingly pertinent.
If so, volume modulated arc therapy may be useful in
reducing overall treatment time and hence organ motion
uncertainty.










pHART7 and 8 30 patients
(8Gy per fraction) VMAT
0.03 (1.23) 0.18 (1.55) 0.37 (1.95)
pHART6 25 patients
(8Gy per fraction) IMRT
0.27 (1.26) 0.30 (1.46) 0.79 (1.99)
Previous Study* (7Gy per
fraction) IMRT
0.03 (0.61) 0.21 (1.50) 0.86 (1.73)
Previous study** (2 Gy per
fraction)
0.14 (0.92) 0.45 (1.27) 0.72 (1.80)
*P. Cheung et al. Int. J. Radiation Oncology Biol. Phys., Vol. 62, pp.
418–425, 2005.
**H. Quon et al. Clinical Oncology, Vol. 24, pp. 640-645, 2012.
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real-time intra-fraction tracking of prostate motion.
Examining the displacement of fiducial markers between
pre- and post-treatment imaging only provides a single
picture during a dynamic process, and does not capture
all potential movement of the prostate. Real-time track-
ing with implanted via markers has previously been
investigated with the Calypso system and more recently
with on-board KV imaging [8]. This study did not look
to assess pure rotational displacement of the prostate. It
is known that rotational motion can be accounted for, in
part, by translational displacement, however the relative
contribution of each was not assessed in this study. Fur-
thermore, potential deformation of the prostate or dis-
placement of fiducials was not taken into account in this
study, however both of these are thought to have min-
imal impact [22-24]. Finally, this study examined only
the geographic changes in the prostate, however the ac-
cumulated dosimetric changes and the potential clinical
consequences are clearly important aspects [24-26].
Conclusion
The prostatic displacement over the course of hypofrac-
tionated radiotherapy, delivered via VMAT, continues to
be small. This suggests that the margins utilized inTable 2 Calculated PTV margin based on Van Herk
















Previous Study* (7Gy per
fraction) IMRT
1.40 4.40 5.20
*H. Quon et al. Clinical Oncology, Vol. 24, pp. 640-645, 2012.standard fixed-angle hypofractionated IMRT are adequate.
An inherent benefit of VMAT is shorter treatment times,
which becomes progressively more significant as the use
and degree of hypofractionation increases. A secondary
benefit of shortening treatment times may be to limit the
organ motion uncertainty that would otherwise be associ-
ated with this hypofractionation.
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